Drug Trial Radar · NCT04706910
18F-DOPA II - PET Imaging Optimization
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Jan 20, 2021
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- University of AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.
Conditions
- Congenital Hyperinsulinism
- Neuroblastoma
- Parkinson Disease
- Lewy Body Disease
- Neuroendocrine Tumors
- Brain Tumor
Interventions
18F-DOPADrug
All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
Furosemide InjectionDrug
Some participants will receive an intravenous injection of furosemide (40mg, single dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimum lesion detectibility (size)Time frame: Within 1 month of PET/CT scan
- Assessment of bladder activityTime frame: Within 1 month of PET/CT scan
- Assessment of bladder activity artifactTime frame: Within 1 month of PET/CT scan
- Minimum lesion detectability (SUV)Time frame: Within 1 month of PET/CT scan
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WC Mackenzie Health Science Centre / University of Alberta Hospital
Edmonton, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.